Navigation Links
Orexigen® Therapeutics Announces Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
Date:9/29/2011

SAN DIEGO, Sept. 29, 2011 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), today announced multiple Contrave® (naltrexone sustained release (SR)/bupropion SR) abstracts accepted for poster presentations and an oral presentation at the upcoming 29th Annual Scientific Meeting of The Obesity Society. This meeting will be held October 1-5, 2011 in Orlando, FL at the Orlando World Center Marriott.

Details on the presentation times are as follows:Monday, October 3, 2011 – Abstract #598-P, Presentation time 12:30-1:30PM EDT, Cypress BallroomPresenter: Robert Chilton, DO; University of Texas Health Science Center, San Antonio, TX, USA.Title: Naltrexone SR/Bupropion SR Combination Therapy Improves Predicted 10-Year Risk of Cardiovascular Disease, Coronary Heart Disease, Myocardial Infarction, and Congestive Heart FailureMonday, October 3, 2011 – Abstract #605-P, Presentation time 12:30-1:30PM EDT, Cypress BallroomPresenter: Ken Fujioka, MD; Scripps Clinic, La Jolla, CA, USA.Title: Completion of 56 Weeks of Naltrexone SR/Bupropion SR Combination Therapy Increases Likelihood of Achieving Improvements in Markers of Cardiometabolic Risk Associated with Clinically Meaningful Weight LossMonday, October 3, 2011 – Abstract #607-P, Presentation time 12:30-1:30PM EDT, Cypress BallroomPresenter: Patrick O'Neil, PhD; Medical University of South Carolina, Charleston, SC, USA.Title: Naltrexone SR/Bupropion SR and Intensive Behavioral Modification Combination Increases the Likelihood of Achieving Early and Sustained Weight Loss and Associated Improvement in Markers of Cardiometabolic RiskMonday, October 3, 2011 – Abstract #49-OR, Presentation time 3:15-4:45PM EDT, "Intervention and Clinical Studies - Surgery/Drugs" SessionPresenter: Gene-Jack Wang, MD; Brookhaven National Laboratory, Upton, NY Title: Reduced responses to food cue after combined therapy
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Orexigen® Therapeutics Presents Additional Contrave® Data from Phase 3 COR-II Trial on 24-Hour Ambulatory Blood Pressure Monitoring
2. Orexigen® Therapeutics Announces Upcoming Data Presentation at the American College of Cardiology Annual Scientific Meeting
3. Orexigen® Therapeutics Announces Corporate Realignment
4. Orexigen® Therapeutics to Present at JP Morgan Healthcare Conference
5. Orexigen® Therapeutics Schedules November 3, 2010 Webcast Discussion of Financial Results for the Third Quarter Ended September 30, 2010
6. Orexigen® Therapeutics Announces Upcoming Data Presentations at the 28th Annual Scientific Meeting of The Obesity Society
7. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
8. ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
9. Healthpoint Biotherapeutics to Present at UBS Global Life Sciences Conference
10. PharmaVentures Engaged by Astex Therapeutics to Assist in the Divestment of US Facility
11. CMC Biologics Licenses Its CHEF1® Expression System to Oxford BioTherapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... TORONTO , April 1, 2015 /PRNewswire/ - ... Securities Exchange: PBT.U), is pleased to announce that ... holds 54% equity, has entered into an agreement ... Biohaven,s first clinical trial with their lead compound ... the identification and development of clinical stage neuroscience ...
(Date:4/1/2015)... 2014 /CNW/ - Canada,s Research-Based Pharmaceutical ... newly released report on Cost Drivers of Public Drug Plans ... to the report, the rates of change in drug costs ... of -0.8 percent in 2012/13 for a number of select ... examines the costs of medicines without considering their overall impact ...
(Date:4/1/2015)... Los Angeles, CA (PRWEB) April 01, 2015 ... portable reader that can read both chromatographic and fluorescent ... a leading supplier of high performance, quantitative readers and ... readers globally. The HRDR-400 is a first of its ... capabilities in one instrument. , Dr. Neven Karlovac, ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 National recruitment ... the placement of Brad Allen as Head of Sales ... the health system market. , Allen brings over ... and sales at a number of companies including Dell ... knowledge and experience were a perfect fit for accomplishing ...
Breaking Biology Technology:Portage's Biohaven Announces Agreement with inVentiv Health 2Portage's Biohaven Announces Agreement with inVentiv Health 3Rx&D responds to PMPRB report: overall impact of medicines must always be considered 2Holomic to Introduce the First Dual, Chromatographic and Fluorescent Rapid Test Reader, the HRDR-400 2Slone Partners Fills Head of Sales at Optimal Medicine 2
... , , , , , , ... CHBT ) ("China-Biotics", "the Company"), a leading Chinese firm,specializing in ... its financial results for,the third quarter of its 2010 fiscal year, ... Third Quarter 2010 Highlights, -- Net sales increased ...
... , NEW YORK , Feb. 10 ... Board: ILNS), a biopharmaceutical company focused on development of ... that several of its significant shareholders (the "Interested Shareholders") ... the Company and assist the Company in its efforts ...
... , SILVER SPRING, Md. , and ... a wholly-owned subsidiary of United Therapeutics Corporation (Nasdaq: UTHR ... Agreement with ImmuneWorks, Inc. to pursue development of ImmuneWorks, lead ... for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and Primary ...
Cached Biology Technology:China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 2China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 3China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 4China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 5China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 6China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 7China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 8China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 9China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 10China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 11China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 12China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 13Intellect Neurosciences, Inc. Announces Preliminary Agreement with Significant Shareholders to Provide Interim Funding and Assist the Company in Efforts to Secure Additional Financing 2Intellect Neurosciences, Inc. Announces Preliminary Agreement with Significant Shareholders to Provide Interim Funding and Assist the Company in Efforts to Secure Additional Financing 3Intellect Neurosciences, Inc. Announces Preliminary Agreement with Significant Shareholders to Provide Interim Funding and Assist the Company in Efforts to Secure Additional Financing 4Lung Rx and ImmuneWorks Announce Collaboration in Idiopathic Pulmonary Fibrosis and Primary Graft Dysfunction 2Lung Rx and ImmuneWorks Announce Collaboration in Idiopathic Pulmonary Fibrosis and Primary Graft Dysfunction 3
(Date:3/31/2015)... , March 31, 2015   Guidepoint , a ... of the Post-Surgical Pain Management TRACKER, part of the ... usage trends in the medical device and therapeutics markets. ... data including treatment volumes, market share, and adoption rates ... associated with joint surgery. The Post-Surgical Pain ...
(Date:3/24/2015)... and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has announced the addition ... Report" report to their offering. This report analyzes ... by the following Segments: Face Biometrics, and Voice Biometrics. The report ... , Japan , Europe , ... & Africa , and Latin America ...
(Date:3/23/2015)... --  HOYOS Labs , a leading global authentication infrastructure ... Company will demonstrate multiple biometrics-based technologies under its identity ... on March 23 through 25, 2015, in ... IEEE Biometric Open Protocol Standard; free biometrics-based consumer app, ... system. BOPS was invented by HOYOS Labs and contributed ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... release is available in German . ... has substantially increased around the world. As a team of ... Technical University of Dresden and the University of Freiburg headed ... temporal trends of global pollination benefit" in the open-access journal ...
... - Researchers at the Centre for Addiction and Mental Health ... form of intellectual disability, as well as how it likely ... Scientist Dr. John Vincent and his team found a mutation ... a finding to be published in the May issue of ...
... successful in attracting funding of an Alexander von Humboldt ... response to an application to appoint Professor Dr. Wolfram ... the USA, to the Center for Thrombosis and Hemostasis ... announced jointly by the Alexander von Humboldt Foundation and ...
Cached Biology News:Global prices of pollination-dependent products such as coffee could rise in the long term 2Global prices of pollination-dependent products such as coffee could rise in the long term 3New form of intellectual disability discovered 2Mainz University Medical Center attracts funding of Alexander von Humboldt Professorship 2Mainz University Medical Center attracts funding of Alexander von Humboldt Professorship 3